| | Webinar: How Providence is Tapping into the Benefits of Patient Activation Tuesday, November 10 | 1pm ET / 10am PT Our healthcare industry has only begun to tap the benefits of patient activation to avoid disruption & improve clinical outcomes, operational efficiency & financial performance. In this session, a panel of experts will review Providence’s My COVID Diary & My Surgical Journey projects & their ability to deliver patient-centric care, & measurable quality, revenue & patient satisfaction improvements. Register Now! |
Eli Lilly nabs $375M deal to supply COVID-19 antibody to U.S. government despite trial failure Manufacturing delays push Novavax's COVID-19 vax trial to end of November Experts propose how to equally distribute COVID-19 vaccine Novartis taps Molecular Partners for a new way to defeat COVID-19 CVS to add 1K rapid-result COVID-19 test sites at pharmacies Sanofi, GSK to provide 200M coronavirus vaccines to COVAX for equitable distribution FDA clears Abiomed's Breethe lung life support system, enabling use in COVID-19 Moody's: Supply chain changes due to COVID-19 to cause hospital costs to increase Biopharma roundup: Abiomed's compact life support system snags FDA clearance GSK's vaccines—especially Shingrix—typically drive growth. Amid COVID-19, they're a drag Willis Towers Watson: 44% of employees have deferred care due to COVID-19 Patient enrollment for trials back to pre-COVID-19 levels: report Featured Story | By Arlene Weintraub One day after the NIH stopped a trial of Eli Lilly's COVID-19 antibody in hospitalized patients for lack of efficacy—and three weeks after reporting mixed data in patients with milder disease—the company struck a $375 million deal to supply the antibody to the U.S. government. It's a big bet by both parties that the drug will, in fact, work. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up vaccine manufacturing. It aims to kick off the study at the end of November. The news comes as the company ramps up a separate phase 3 study for the vaccine in the U.K., which has expanded to 15,000 patients from its original goal of 10,000. read more By Robert King A new JAMA article lays out a potential approach for how to distribute doses of a COVID-19 vaccine, which is likely to be in short supply. read more By Ben Adams Novartis is spending $69 million upfront on a pair of experimental drugs from Fierce 15 winner Molecular Partners. read more By Paige Minemyer CVS Health is adding 1,000 more rapid-result testing sites at its pharmacies by the end of the year. read more By Eric Sagonowsky Sanofi and GlaxoSmithKline aren’t the front-runners in the race for a COVID-19 vaccine race, but execs for the companies have said they expect to play an important role in the global vaccination push. Now, the partners are backing that up with an agreement to provide 200 million doses of their vaccine to COVAX, a global effort to develop, produce and equitably distribute doses. read more By Conor Hale As the number of daily coronavirus cases in the U.S. once again begins to climb to new records, the FDA granted a 510(k) clearance to Abiomed’s compact, all-in-one life support system for bypassing a patient’s struggling heart and lungs. read more By Robert King A new Moody's analysis finds the global supply chain is going to become more fragmented and less globalized, which could lead to higher costs for hospitals to get personal protective equipment and fund new construction projects. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner GSK's shingles and meningitis B vaccines took a pandemic hit in the third quarter. The FDA cleared Abiomed's compact life support system, teeing up use in COVID. Covaxx teamed up with Maersk to hash out global shot distribution. And clinical trials are rebounding to pre-pandemic levels. read more By Eric Sagonowsky GlaxoSmithKline isn't alone in facing a slowdown amid the COVID-19 pandemic, but its big vaccines presence makes 2020 particularly tough for the British drugmaker. Perhaps the company’s most notable laggard now is Shingrix, its fast-launching, growth-fueling shingles vaccine. read more By Paige Minemyer Nearly half of employees have deferred care amid the pandemic, according to a new survey from Willis Towers Watson. read more By Ben Adams A new report out by study management firm Greenphire says patient enrollment for global clinical trials “has returned to pre-COVID levels.” read more |
